Background: Retinal vasculitis is a common manifestation of infections affecting the posterior segment. The purpose of this review is to describe the main characteristics of infectious retinal vasculitis, with an emphasis on its associated specific clinical manifestations.
Summary: Retinal vasculitis is usually associated with retinal or choroidal involvement when infectious etiology is present. It may be caused by bacterial, viral, fungal or parasitic infection. Its prevalence and the spectrum of etiologies show geographical variations. Infectious vasculitis tends to exhibit ischemic areas, arterial or venous sheathing or occlusion, while non-infectious retinal vasculitis is predominantly associated with capillary vasculitis.
Key Messages: Recognizing the features of infectious retinal vasculitis, along with associated ocular and systemic signs, patient habits, and origin, enables the physician to suspect the potential causative etiology of the condition, facilitating more effective management of affected patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000545044 | DOI Listing |
Ophthalmic Genet
March 2025
Ophthalmology, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia.
Background: ROSAH syndrome is an autosomal dominant systemic disease featuring etinal dystrophy, ptic nerve edema, plenomegaly, nhidrosis and migrainous eadache. Ocular manifestation of ROSAH syndrome can simulate posterior uveitis, vasculitis, generalized retinal dystrophy and neuroretinitis.
Purpose: To report a case of a 17-year-old female presenting with recurrent vitreous hemorrhage on a background of dental anomalies and anhidrosis.
Arch Soc Esp Oftalmol (Engl Ed)
March 2025
Clínica del Ojo, La Paz, Bolivia.
Anti-vascular endothelial growth factor drugs are the treatment of choice for macular edema due to venous occlusions. While rare, they have been associated with some uncommon adverse effects. We present a case of retinal vasculitis associated with bevacizumab in a72-year-old woman who presented to our clinic with sudden visual acuity loss in her left eye due to macular edema following central vein occlusion.
View Article and Find Full Text PDFOcul Immunol Inflamm
March 2025
Poostchi Ophthalmology Research Center, Department of Ophthalmology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Purpose: To evaluate the risk of retinal vasculitis and related adverse events (AEs) among five commercially available anti-vascular endothelial growth factor (anti-VEGF) agents using data from the FDA Adverse Event Reporting System (FAERS).
Methods: A retrospective pharmacovigilance study was conducted using FAERS data from Q1 2004 to Q4 2024. Adverse drug reactions (ADRs) were categorized using the Medical Dictionary for Regulatory Activities (MedDRA), with "Retinal Vasculitis" as the primary outcome and "Uveitis" and "Vitritis" as secondary outcomes.
Clin Exp Ophthalmol
March 2025
Department of Ophthalmology, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia.
Background: Intravitreal bevacizumab has been used off-label to treat multiple ocular conditions for almost two decades. Reference bevacizumab, Avastin, was discontinued in Australia in 2021. A bevacizumab biosimilar, MVASI, was approved by the Therapeutic Goods Administration for the treatment of metastatic cancer in 2020.
View Article and Find Full Text PDFBackground: Retinal vasculitis is a common manifestation of infections affecting the posterior segment. The purpose of this review is to describe the main characteristics of infectious retinal vasculitis, with an emphasis on its associated specific clinical manifestations.
Summary: Retinal vasculitis is usually associated with retinal or choroidal involvement when infectious etiology is present.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!